Literature DB >> 12594808

Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.

Li-Wu Qian1, Kazuhiro Mizumoto, Naoki Inadome, Eishi Nagai, Norihiro Sato, Kunio Matsumoto, Toshikazu Nakamura, Masao Tanaka.   

Abstract

Hepatocyte growth factor (HGF) is a stromal-derived cytokine that plays a crucial role in invasion and metastasis of tumor cells through the interaction with HGF receptor, c-Met, which is frequently overexpressed in pancreatic cancer. The present study was designed to investigate the change in HGF receptor and HGF-mediated signaling after irradiation in pancreatic cancer cells. Six cell lines from human pancreatic cancer were included in the study. Gamma-radiation was used for irradiation treatment. The changes in expression levels of c-Met were evaluated by immunoblot and confirmed morphologically by indirect immunofluorescence staining. Whether the resultant alteration in c-Met would cascade as biologically usable signals upon HGF ligation was traced by receptor tyrosine phosphorylation analysis and mitogen activated protein kinase (MAP kinase or MAPK) activity assay. The various biological responses to HGF (including cell proliferation, cell scattering, migration and invasion) were evaluated as well. We also used a 4-kringle antagonist of HGF, NK4, to block the HGF/c-Met signaling pathway. Both immunoblot and immunofluorescent analysis showed moderate increased expression of c-Met in 3 of 6 pancreatic cancer cell lines after irradiation. The actions seemed to be dose-responsible, which began at 3 hr and reached its peak value at 24 hr following irradiation. The radiation-increased expression of c-Met could transform into magnifying receptor tyrosine phosphorylation reaction and MAP kinase activity once the ligand was added, fairly corresponding with alteration in the receptor. Sequentially, the cellular responses to HGF, including scattering and invasion but not proliferation, were enhanced. Also, in the presence of HGF, the elevated receptor could help to recover the radiation-compromised cell migration. A recombinant HGF antagonist, NK4 could effectively block these aberrant effects activated by irradiation both in molecular and cellular levels, thus suggesting the deep involvement of the c-Met/HGF pathway in the enhanced malignant potential after irradiation. These results suggest that radiation may promote HGF-induced malignant biological behaviors of certain pancreatic cancer cells through the up-regulated HGF/c-Met signal pathway. Selectively targeted blockade of the HGF/c-Met pathway could help to abolish the enforced malignant behavior of tumor cells by irradiation and therefore may improve the efficacy of radiotherapy for pancreatic cancer. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594808     DOI: 10.1002/ijc.10997

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression.

Authors:  Vikas Bhardwaj; Yanai Zhan; Maria Angelica Cortez; Kie Kian Ang; David Molkentine; Anupama Munshi; Uma Raju; Ritsuko Komaki; John V Heymach; James Welsh
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

Review 2.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Authors:  Ignacio Garrido-Laguna; Manuel Hidalgo
Journal:  Nat Rev Clin Oncol       Date:  2015-03-31       Impact factor: 66.675

Review 3.  MET overexpression and gene amplification in NSCLC: a clinical perspective.

Authors:  Lorenza Landi; Gabriele Minuti; Armida D'Incecco; Jessica Salvini; Federico Cappuzzo
Journal:  Lung Cancer (Auckl)       Date:  2013-06-18

4.  Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Authors:  Cristina Basilico; Anna Hultberg; Christophe Blanchetot; Natalie de Jonge; Els Festjens; Valérie Hanssens; Sjudry-Ilona Osepa; Gitte De Boeck; Alessia Mira; Manuela Cazzanti; Virginia Morello; Torsten Dreier; Michael Saunders; Hans de Haard; Paolo Michieli
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

Review 5.  Role of HGF/MET axis in resistance of lung cancer to contemporary management.

Authors:  Kanwal Pratap Singh Raghav; Ana Maria Gonzalez-Angulo; George R Blumenschein
Journal:  Transl Lung Cancer Res       Date:  2012-09

Review 6.  Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.

Authors:  Vikas Bhardwaj; Tina Cascone; Maria Angelica Cortez; Arya Amini; Jaden Evans; Ritsuko U Komaki; John V Heymach; James W Welsh
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

7.  Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102.

Authors:  Ian M Buchanan; Tamalee Scott; Anita T Tandle; William E Burgan; Teresa L Burgess; Philip J Tofilon; Kevin Camphausen
Journal:  J Cell Mol Med       Date:  2010-07-12       Impact factor: 5.310

8.  PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.

Authors:  Joseph B Mascarenhas; Kacey P Young; Erica L Littlejohn; Brian K Yoo; Ravi Salgia; Deborah Lang
Journal:  J Biol Chem       Date:  2009-08-03       Impact factor: 5.157

Review 9.  Effects of radiation on metastasis and tumor cell migration.

Authors:  Marta Vilalta; Marjan Rafat; Edward E Graves
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

10.  Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.

Authors:  Barbara Sennino; Toshina Ishiguro-Oonuma; Ying Wei; Ryan M Naylor; Casey W Williamson; Vikash Bhagwandin; Sebastien P Tabruyn; Weon-Kyoo You; Harold A Chapman; James G Christensen; Dana T Aftab; Donald M McDonald
Journal:  Cancer Discov       Date:  2012-02-24       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.